Crispr Therapeutics AG vs HCA Health Inc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while HCA Health Inc trades at $411.49 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 17× Crispr Therapeutics AG's market cap, and HCA Health Inc pays a 0.76% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HCA | |
|---|---|---|
Market Cap | $5.23B | $89.08B |
Sector | Health | Health |
52-Week High | $76.78 | $545.13 |
52-Week Low | $44.34 | $361.32 |
Enterprise Value | $3.65B | $139.62B |
Dividend Yield | — | 0.76% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →